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In recent weeks, PLoS Medicine has
published several research papers that
challenge current health care practices.
One study found that a campaign to
promote solar drinking water disinfection
did not substantially decrease rates of
childhood diarrhea [1]. Another found
more than a doubled risk of hospitalization
for bradycardia in older people taking
cholinesterase inhibitors used to treat
cognitive impairment [2]. A systematic
review failed to find any randomized trials
that support the internationally recom-
mended retreatment regimen for tubercu-
losis [3]. Finally, a study of one of the main
international registries for clinical trials,
ClinicalTrials.gov, found that require-
ments to register clinical trials have not
resulted in high publication rates [4].
A study that questions the accepted or
desired way of doing things can be at least
as important as one that supports a new
approach. Physicians mindful of Hippo-
crates’ vow to ‘‘first do no harm’’ should
take a keen interest in such studies, for
while a new intervention that proves
efficacious in clinical trials may pass slowly,
if at all, through practical barriers to
effective implementation, the demonstra-
tionthatanexistingpracticeisineffective or
potentially harmful can (or should) prompt
a rapid change in research agendas, policy,
and clinical care. Knowing what doesn’t
work is particularly useful in efforts to
control medical spending, where redirect-
ing limited resources away from ineffective
interventions is of obvious benefit.
Studies that convincingly refute accept-
ed practice are particularly well suited to
open-access publication. Only universal
availability of unexpected or, from a
marketing standpoint, unfavorable data
can effectively guard against publication
bias that may favor results that advance
specific vested interests. Such bias can
skew the medical literature toward opti-
mistic but incomplete data and can
prevent consideration of the full evidence
in policy-changing systematic reviews.
Open-access journals are, by definition,
free from the temptation to reap profits by
selling reprints of research papers, and
therefore need have no reservations about
publishing papers that, by failing to
promote a new intervention, create little
commercial demand for reprints. Open-
access journals also need not be concerned
if negative efficacy studies don’t receive
the kind of media coverage that attracts
paying readers in large numbers.
The importance of valid negative re-
sults, and of their immediate and open
availability, is of particular pertinence in
the movement to undertake comparative
effectiveness research (CER), which earlier
this year received US$1.1 billion in United
States government funding [5]. In a report
commissioned by Congress as part of the
American Recovery and Reinvestment
Act, the Institute of Medicine (IOM)
defined comparative effectiveness research
as ‘‘the generation and synthesis of
evidence that compares the benefits and
harms of alternative methods to prevent,
diagnose, treat, and monitor a clinical
condition or to improve the delivery of
care. The purpose of CER is to assist
consumers, clinicians, purchasers, and
policy makers to make informed decisions
that will improve health care at both the
individual and population levels.’’ In
setting priority areas for comparative
effectiveness research, the IOM report
noted that ‘‘priorities should be balanced
in the primary methodologies employed to
conduct them: systematic reviews, data-
base research, observational studies, and
randomized trials’’[6].
In calling for a wide range of study
designs to assess real-world outcomes, this
initiative raises the need for broad trans-
parency in the analysis and reporting of
study results. In recent years, journals and
governments have recognized the need for
openness in the registration and reporting
of clinical trials [7], which are designed
primarily to determine safety and efficacy.
In CER, which will include studies of many
types, practices that distort the scientific
evidence base—such as ‘‘cherry picking’’ for
publication only those studies describing a
desired outcome, or ‘‘fishing’’ from an ocean
of possible analyses only those that might
support favorable (but statistically invalid)
conclusions—have the potential to affect
policy, practice, and profits to an even
g r e a t e rd e g r e et h a nt h e yh a v ed o n ei nt h e
context of traditional efficacy trials. Regis-
tering only clinical trials is therefore insuffi-
cient to protect against selective publication
or reporting in studies of other designs,
which will play an increasing rolein assessing
clinical effectiveness. In other words, a
journal that adheres to now-standard re-
quirements relating to trial registration might
duly intercept an unregistered clinical trial of
an abandoned intervention that will not
affect care, but might have no way of
knowing that a large data-mining study
intended to influence treatment guidelines
is presenting a non-prespecified (‘‘post-hoc’’)
analysis as its primary outcome. As the IOM
report observes:
Citation: The PLoS Medicine Editors (2009) Ensuring Integrity in Comparative Effectiveness Research:
Accentuate the Negative. PLoS Med 6(9): e1000152. doi:10.1371/journal.pmed.1000152
Published September 29, 2009
Copyright:  2009 The PLoS Medicine Editors. This is an open-access article distributed under the terms of
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original author and source are credited.
Funding: The authors are each paid a salary by the Public Library of Science, and they wrote this editorial
during their salaried time.
Competing Interests: The authors’ individual competing interests are at http://www.plosmedicine.org/static/
editorsInterests.action. PLoS is funded partly through manuscript publication charges, but the PLoS Medicine
Editors are paid a fixed salary (their salary is not linked to the number of papers published in the journal).
Abbreviations: IOM, Institute of Medicine; CER, comparative effectiveness research.
* E-mail: medicine_editors@plos.org
The PLoS Medicine Editors are Virginia Barbour, Jocalyn Clark, Susan Jones, Larry Peiperl, Emma Veitch, and
Gavin Yamey. However, Gavin Yamey was on sabbatical during the writing of this editorial.
Provenance: Written by editorial staff; not externally peer reviewed.
PLoS Medicine | www.plosmedicine.org 1 September 2009 | Volume 6 | Issue 9 | e1000152‘‘Objectivity will be central to the
public’s trust and confidence in the
integrity of the CER Program.
Conflict of interest and bias in
clinical research—published in even
the most respected medical jour-
nals—is well-documented…. Selec-
tive reporting or publication bias is
common. Positive findings are more
likely to be published than negative
results…. In addition, there have
been significant instances in which
leading journals have not sufficiently
enforced disclosure requirements for
authors and reviewers…. CER is as
vulnerable to bias and conflict of
interest as any other area of medical
research. The ultimate value of the
CER enterprise will rest, in part, on
vigilant attention to these issues’’
[6].
CER thus provides a wake-up call that
draws attention to the potential pitfalls of
bias in research more generally, and
highlights the need for openness in the
design and reporting of all types of
research, in order to prevent ulterior
interests—whether financial or political—
from slanting data in a manner that could
directly affect the medical care of large
populations. If studies of many designs,
and those producing negative as well as
positive assessments, are to play a larger
role in shaping clinical practice, then
transparency in the design and reporting
of these studies will be essential. The
affected public should demand prospective
registration of all research—regardless of
study design—that is aimed at assessing
the effectiveness of clinical practices.
Venues in which to begin are available;
ClinicalTrials.gov already accommodates
registration of observational as well as
interventional studies. With heightened
vigilance on the part of journal editors
and policymakers, such registration, by
laying out intended analyses in advance,
can prevent studies from shape-shifting or
simply vanishing without explanation be-
tween registration and publication, as
seems to be happening with many clinical
trials [4]. Moreover, reporting guidelines,
such as those disseminated by the EQUA-
TOR Network [8], are not merely aids for
structuring manuscripts, but provide valu-
able tools for designing studies that are
transparent to critical evaluation.
Medical practice stands to benefit from
a clearer understanding of what works
effectively and what doesn’t. Such knowl-
edge can only emerge from unbiased
reporting of the research that supports it,
including data that contest prevailing
practices. The integrity of the medical
literature requires that negative results
assume their rightful place alongside those
that support blockbuster sales and break-
through headlines.
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